샘플 요청 목록

 카트 문의
시장보고서
상품코드
2156157

소 호흡기질환 치료 시장

Bovine Respiratory Disease Treatment
발행일: | 리서치사: 구분자 Market Glass, Inc. | 페이지 정보: 영문 354 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 7,938,000
PDF & Excel (Team License: Up to 10 users) help
PDF & Excel 보고서를 동일 기업 내 최대 10명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기가 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 이용자 1명당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 11,115 금액 안내 화살표 ￦ 15,083,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 23,815,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 소 호흡기질환 치료제 시장은 2032년까지 20억 달러에 달할 것으로 전망됩니다.

2025년 12억 달러로 추정되는 세계 소 호흡기질환 치료 시장은 2025-2032년의 분석 기간 동안 연평균 성장률(CAGR) 7.8%를 기록하며, 2032년까지 20억 달러에 달할 것으로 예측됩니다. 본 보고서에서 분석 대상으로 삼고 있는 부문 중 하나인 ‘항생제’는 9.2%의 연평균 성장률(CAGR)을 기록하며, 분석 기간이 끝날 때까지 8억 110만 달러에 달할 것으로 예측됩니다. ‘항염증제’ 부문의 성장률은 분석 기간 동안 연평균 8.5%의 성장률을 보일 것으로 추정됩니다.

미국 시장은 3억 2,320만 달러로 추산되는 반면, 중국은 연평균 성장률(CAGR) 12.1%를 나타낼 것으로 예측됩니다.

미국의 소 호흡기질환 치료제 시장은 2025년에 3억 2,320만 달러로 추산됩니다. 세계 2위의 경제 규모를 자랑하는 중국은 2025-2032년의 분석 기간 동안 연평균 성장률(CAGR) 12.1%를 기록하며, 2032년까지 시장 규모가 4억 4,290만 달러에 달할 것으로 예측됩니다. 그 밖의 주목할 만한 지역 시장으로는 일본과 캐나다가 꼽히며, 분석 기간 동안 각각 연평균 성장률(CAGR) 4.1% 및 7.4%를 나타낼 것으로 예측됩니다. 유럽 내에서는 독일이 연평균 성장률(CAGR) 약 5.4%를 나타낼 것으로 예측됩니다.

세계 소 호흡기질환 치료 시장 - 주요 동향 및 촉진요인 개요

소 호흡기질환이란 무엇이며, 왜 큰 우려 사항이 되고 있는가?

소 호흡기질환(BRD)은 세계 소 사육군, 특히 육우 및 젖소 사육군에 영향을 미치는 중대한 건강 문제입니다. 이 질환은 운송 직후의 소에서 흔히 나타나기 때문에 ‘운송열’이라고도 불리지만, 그 영향은 훨씬 광범위하여 모든 연령대와 유형의 소에 영향을 미칩니다. 이 질환은 운송, 무리 합류, 환경 변화와 같은 다양한 스트레스 요인과 바이러스, 세균, 마이코플라스마 등의 병원체 간의 상호작용에 의해 유발되는 복잡하고 다인자적인 질환입니다. BRD는 체중 증가 저하, 사료 전환율 상승, 사망률 증가, 나아가 치료 및 예방 조치에 드는 비용으로 인해 심각한 경제적 손실을 초래하는 것으로 알려져 있습니다. 또한 동물 복지에도 막대한 영향을 미치고 있어, 보다 효과적이고 인도적인 치료법의 확립이 요구되고 있습니다. BRD의 복잡성과 다면적인 특성으로 인해, 그 치료는 수의학 및 가축 관리 분야에서 매우 중요한 초점이 되고 있습니다.

소 호흡기질환에 대한 현재의 치료 전략은 어떻게 진화하고 있는가?

최근 이 질환의 병태에 대한 이해가 깊어지고 새로운 치료법이 개발됨에 따라, 소 호흡기질환 치료에서 현저한 진전이 나타나고 있습니다. 기존의 치료 전략에서는 일반적으로 질환의 세균성 요인을 대상으로 한 광범위 항생제의 사용에 더해, 발열이나 통증을 완화하기 위한 항염증제 등의 지지 요법이 시행되어 왔습니다. 그러나 항생제 내성과 이러한 치료법의 유효성에 대한 우려로 인해, 보다 표적화된 접근 방식의 모색이 진행되고 있습니다. 새로운 치료법은 정밀 의학에 점점 더 중점을 두고 있습니다. 이는 진단 도구를 사용하여 특정 BRD 사례와 관련된 병원체를 규명함으로써, 보다 개인화된 치료 프로토콜을 가능하게 하는 것입니다. 또한, 감염을 더 효과적으로 퇴치하기 위해 동물의 면역 반응을 강화하는 것을 목표로 하는 면역 조절 요법에 대한 관심도 높아지고 있습니다. 이러한 진전은 회복률을 향상시킬 뿐만 아니라, 항생제의 과다 사용에 따른 위험을 줄이는 데에도 기여하는 보다 지속 가능하고 효과적인 치료법으로의 전환을 보여줍니다.

소 호흡기질환 예방의 새로운 동향은 무엇인가?

소 호흡기질환(BRD) 예방은 발병 후 치료보다 예방이 비용 대비 효과가 높고 유익하다는 인식이 업계 내에서 확산됨에 따라 중요한 초점 영역이 되고 있습니다. 백신 접종 프로그램은 BRD 예방의 기반이며, 가장 흔한 바이러스성 및 세균성 병원체를 표적으로 하는 백신을 이용할 수 있습니다. 비강 스프레이와 같은 새로운 투여 방법을 통해 투여할 수 있는 백신을 포함하여, 더 효과적인 백신의 개발은 업계의 지속적인 동향으로 자리 잡고 있습니다. 또 다른 중요한 동향은 정밀 축산 기술의 활용입니다. 이는 데이터 분석, 센서, 모니터링 시스템을 활용하여 위험에 처한 개체를 조기에 식별하고, 질병이 확산되기 전에 예방 조치를 취하는 것입니다. 이러한 기술을 통해 소 무리를 지속적으로 감시할 수 있게 되어, BRD 발생률을 대폭 낮출 수 있는 조기 개입이 가능해집니다. 또한, 운송 중 스트레스 완화, 영양 관리 최적화, 적절한 사육 환경 확보 등 소 무리 관리 전반의 개선이 점점 더 중요시되고 있으며, 이 모든 것이 질병 발생 위험 감소에 기여하고 있습니다.

소 호흡기질환 치료 시장의 성장을 견인하고 있는 요인은 무엇일까？

소 호흡기질환 치료 시장의 성장은 기술 발전, 최종 사용자의 관행 변화, 그리고 소비자 행동의 변화와 직접적으로 관련된 몇 가지 요인에 의해 주도되고 있습니다. 주요 촉진요인 중 하나는 수의학 분야에서 정밀 의학의 도입이 진행되고 있다는 점입니다. 이를 통해 보다 정확하고 효과적인 치료가 가능해져 회복률 향상과 사망률 감소로 이어지고 있습니다. 특히 개발도상 지역에서의 축산업 확대도 시장 성장을 뒷받침하고 있습니다. 이는 소 사육 두수가 증가함에 따라 효과적인 BRD 치료법에 대한 수요가 높아지고 있기 때문입니다. 또한, 인도적이고 지속 가능한 조건에서 생산된 육류 및 유제품에 대한 소비자 수요가 증가함에 따라, 축산 농가들은 BRD와 같은 질병에 대해 보다 효과적이고 윤리적인 치료 프로토콜을 채택하도록 촉진되고 있습니다. 가축에 대한 항생제 사용을 줄이도록 요구하는 규제적 압력 또한 면역 조절 요법이나 표적 항균 요법과 같은 대체 치료법의 개발 및 도입을 가속화하고 있습니다. 마지막으로, 진단 기술의 발전으로 수의사가 BRD를 신속하고 정확하게 진단하기 쉬워져, 보다 시기적절하고 효과적인 치료가 가능해졌습니다는 점도 시장 확대를 더욱 뒷받침하고 있습니다.

부문:

약제 유형(항생제, 항염증제, 백신, 구충제), 투여 경로(정맥 내 투여, 근육 내 투여, 피하 투여, 경구 투여), 용도(치료 용도, 예방 용도, 진단 용도, 지지 요법 용도)

주요 기업

  • Bayer AG
  • Bimeda Group
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Elanco Animal Health, Inc.
  • IDEXX Laboratories, Inc.
  • Merck &Co., Inc.
  • Vetoquinol S.A.
  • Virbac Corporation
  • Zoetis Services, LLC

해당 분야의 전문가 관점을 바탕으로 합니다-산업계, 기업, 학계에 걸친 분야 전문가들의 관점을 반영하여, 기존에 발표된 조사 결과 이상의 맥락을 더하고 있습니다.

시장의 초기 신호를 포착합니다 -기존의 2차 조사에 완전히 반영되기 전에, 전문가 간의 대화, 기업의 동향, 시장과 관련된 논의를 통해 드러나는 변화를 추적합니다.

광범위하고 검증된 정보 기반을 활용합니다 -컨퍼런스 세션, 기조 연설, 패널 토론, 블로그, 기업의 공시 정보, 연차 보고서, 기관 간행물 및 기타 검증된 정보 출처에서 얻은 인사이트를 통합하고 있습니다.

신호와 전략적 시장 방향성을 연결합니다 - 이러한 관점을 통합하여 시장이 어디로 향하고 있는지, 그 움직임을 주도하는 요인은 무엇인지, 그리고 전략에 있어 가장 중요할 가능성이 있는 동향은 무엇인지 파악합니다.

상세한 기업 정보를 제공합니다 - 시장 수준의 분석에 그치지 않고, 경쟁 환경에 참여하며 그 형성에 기여하고 있는 기업을 상세하게 검증합니다.

주요 지역 시장 점유율을 면밀히 검토합니다 - 단일 세계 시장 점유율 수치만으로는 전체적인 상황을 파악하기 어렵습니다. 경쟁 구도는 지역에 따라 크게 다를 수 있습니다. 분석상 관련성이 있는 경우, Market Glass의 보고서는 각 시장의 구조와 동향에 맞추어 상세도를 조정하여 주요 지역 시장 점유율 분석을 심층적으로 다룹니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 26.10.29

Global Bovine Respiratory Disease Treatment Market to Reach US$2.0 Billion by 2032

The global market for Bovine Respiratory Disease Treatment estimated at US$1.2 Billion in the year 2025, is expected to reach US$2.0 Billion by 2032, growing at a CAGR of 7.8% over the analysis period 2025-2032. Antibiotics Drug Type, one of the segments analyzed in the report, is expected to record a 9.2% CAGR and reach US$801.1 Million by the end of the analysis period. Growth in the Anti-Inflammatories Drug Type segment is estimated at 8.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$323.2 Million While China is Forecast to Grow at 12.1% CAGR

The Bovine Respiratory Disease Treatment market in the U.S. is estimated at US$323.2 Million in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$442.9 Million by the year 2032 trailing a CAGR of 12.1% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Bovine Respiratory Disease Treatment Market - Key Trends and Drivers Summarized

What Is Bovine Respiratory Disease and Why Is It a Major Concern?

Bovine Respiratory Disease (BRD) is a significant health issue affecting cattle populations worldwide, particularly in beef and dairy herds. It is often referred to as "shipping fever" because it commonly occurs in cattle that have been recently transported, but its impact is far broader, affecting all ages and types of cattle. The disease is a complex, multifactorial condition that results from the interaction of various stress factors-such as transportation, co-mingling, and environmental changes-with infectious agents including viruses, bacteria, and mycoplasma. BRD is notorious for causing severe economic losses due to decreased weight gain, higher feed conversion rates, increased mortality, and the cost of treatment and preventive measures. It also has a substantial impact on animal welfare, leading to a push for more effective and humane treatment options. The complexity and multifaceted nature of BRD make its treatment a critical focus area in veterinary medicine and livestock management.

How Are Current Treatment Strategies Evolving for Bovine Respiratory Disease?

In recent years, there have been significant advancements in the treatment of Bovine Respiratory Disease, driven by a better understanding of the disease's pathology and the development of new therapeutic interventions. Traditional treatment strategies have typically involved the use of broad-spectrum antibiotics to target the bacterial component of the disease, alongside supportive care such as anti-inflammatory drugs to reduce fever and pain. However, concerns about antibiotic resistance and the efficacy of such treatments have led to the exploration of more targeted approaches. Newer therapies are increasingly focused on precision medicine, which involves the use of diagnostic tools to identify the specific pathogens involved in a particular case of BRD, allowing for more tailored treatment protocols. Additionally, there has been a growing interest in immunomodulatory therapies that aim to boost the animal’s immune response to fight off the infection more effectively. These advancements represent a shift towards more sustainable and effective treatment regimens that not only improve recovery rates but also help mitigate the risks associated with antibiotic overuse.

What Are the Emerging Trends in Bovine Respiratory Disease Prevention?

The prevention of Bovine Respiratory Disease has become a key area of focus, as the industry recognizes that preventing the disease is more cost-effective and beneficial than treating it after it occurs. Vaccination programs are a cornerstone of BRD prevention, with vaccines available that target the most common viral and bacterial pathogens. The development of more effective vaccines, including those that can be administered through novel delivery methods such as intranasal sprays, is an ongoing trend in the industry. Another significant trend is the use of precision livestock farming techniques, which leverage data analytics, sensors, and monitoring systems to identify at-risk animals early and take preventive measures before the disease can spread. These technologies allow for the continuous monitoring of cattle herds, enabling early intervention that can significantly reduce the incidence of BRD. Additionally, there is a growing emphasis on improving overall herd management practices, such as reducing stress during transportation, optimizing nutrition, and ensuring proper housing conditions, all of which contribute to a lower risk of disease outbreaks.

What Is Driving the Growth of the Bovine Respiratory Disease Treatment Market?

The growth in the Bovine Respiratory Disease treatment market is driven by several factors directly related to technological advancements, changing end-use practices, and evolving consumer behavior. One of the key drivers is the increasing adoption of precision medicine in veterinary care, which allows for more accurate and effective treatments, leading to higher recovery rates and reduced mortality. The expansion of livestock farming, particularly in developing regions, is also fueling market growth, as the demand for effective BRD treatment options rises in tandem with the growth of the cattle population. Moreover, there is a growing consumer demand for meat and dairy products produced under humane and sustainable conditions, which has pushed livestock producers to adopt more effective and ethical treatment protocols for diseases like BRD. Regulatory pressures to reduce antibiotic use in livestock have also accelerated the development and adoption of alternative treatment methods, such as immunomodulatory therapies and targeted antimicrobial therapies. Finally, advancements in diagnostic technologies are making it easier for veterinarians to quickly and accurately diagnose BRD, leading to more timely and effective treatments, further driving the market's expansion.

SCOPE OF STUDY:

The report analyzes the Bovine Respiratory Disease Treatment market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type, Antiparasitics Drug Type); Administration Route (Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route, Oral Administration Route); Application (Therapeutic Application, Prophylactic Application, Diagnostic Application, Supportive Care Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

  • Bayer AG
  • Bimeda Group
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Elanco Animal Health, Inc.
  • IDEXX Laboratories, Inc.
  • Merck & Co., Inc.
  • Vetoquinol S.A.
  • Virbac Corporation
  • Zoetis Services, LLC

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
    • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
    • Bovine Respiratory Disease Treatment - Global Key Competitors Percentage Market Share in 2026 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for 12 Players Worldwide in 2026 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Respiratory Infections Propels Demand for Advanced Treatment Solutions
    • Increasing Focus on Animal Welfare Expands Addressable Market Opportunity for Humane Treatment Options
    • Growing Awareness of Antimicrobial Resistance Strengthens the Business Case for Non-Antibiotic Therapies
    • Innovations in Vaccination Technology Spur Growth in Preventive Care Solutions
    • Regulatory Pressures on Antibiotic Use Throw the Spotlight on Alternative Therapies
    • Here's How Precision Livestock Farming Drives Adoption of Targeted Treatment Approaches
    • Expanding Global Livestock Population Accelerates Demand for Bovine Respiratory Disease Treatments
    • Increasing Integration of Digital Health Tools in Veterinary Care Generates New Market Opportunities
    • Growing Consumer Demand for Quality Meat and Dairy Products Drives Adoption of Effective Disease Management
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Bovine Respiratory Disease Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2020 through 2032
    • TABLE 2: World Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 3: World Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 4: World 13-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
    • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 6: World Historic Review for Antibiotics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 7: World 13-Year Perspective for Antibiotics Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 8: World Recent Past, Current & Future Analysis for Anti-Inflammatories Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 9: World Historic Review for Anti-Inflammatories Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 10: World 13-Year Perspective for Anti-Inflammatories Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 11: World Recent Past, Current & Future Analysis for Vaccines Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 12: World Historic Review for Vaccines Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 13: World 13-Year Perspective for Vaccines Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 14: World Recent Past, Current & Future Analysis for Antiparasitics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 15: World Historic Review for Antiparasitics Drug Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 16: World 13-Year Perspective for Antiparasitics Drug Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 17: World Recent Past, Current & Future Analysis for Intravenous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 18: World Historic Review for Intravenous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 19: World 13-Year Perspective for Intravenous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 20: World Recent Past, Current & Future Analysis for Intramuscular Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 21: World Historic Review for Intramuscular Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 22: World 13-Year Perspective for Intramuscular Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 23: World Recent Past, Current & Future Analysis for Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 24: World Historic Review for Subcutaneous Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 25: World 13-Year Perspective for Subcutaneous Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 27: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 28: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 29: World Recent Past, Current & Future Analysis for Therapeutic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 30: World Historic Review for Therapeutic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 31: World 13-Year Perspective for Therapeutic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 32: World Recent Past, Current & Future Analysis for Prophylactic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 33: World Historic Review for Prophylactic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 34: World 13-Year Perspective for Prophylactic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 35: World Recent Past, Current & Future Analysis for Diagnostic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 36: World Historic Review for Diagnostic Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 37: World 13-Year Perspective for Diagnostic Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
    • TABLE 38: World Recent Past, Current & Future Analysis for Supportive Care Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 39: World Historic Review for Supportive Care Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 40: World 13-Year Perspective for Supportive Care Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

  • UNITED STATES
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 42: USA Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 43: USA 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 44: USA Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 45: USA Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 46: USA 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 47: USA Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 48: USA Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 49: USA 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 51: Canada Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 52: Canada 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 54: Canada Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 55: Canada 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 57: Canada Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 58: Canada 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • JAPAN
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 60: Japan Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 61: Japan 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 63: Japan Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 64: Japan 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 66: Japan Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 67: Japan 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • CHINA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 69: China Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 70: China 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 71: China Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 72: China Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 73: China 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 74: China Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 75: China Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 76: China 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • EUROPE
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 78: Europe Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 79: Europe 13-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 81: Europe Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 82: Europe 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 84: Europe Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 85: Europe 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 87: Europe Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 88: Europe 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • FRANCE
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 90: France Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 91: France 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 92: France Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 93: France Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 94: France 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 95: France Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 96: France Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 97: France 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • GERMANY
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 99: Germany Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 100: Germany 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 102: Germany Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 103: Germany 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 105: Germany Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 106: Germany 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 108: Italy Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 109: Italy 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 111: Italy Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 112: Italy 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 114: Italy Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 115: Italy 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • UNITED KINGDOM
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 117: UK Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 118: UK 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 119: UK Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 120: UK Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 121: UK 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 122: UK Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 123: UK Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 124: UK 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 126: Spain Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 127: Spain 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 129: Spain Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 130: Spain 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 132: Spain Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 133: Spain 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 135: Russia Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 136: Russia 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 138: Russia Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 139: Russia 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 141: Russia Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 142: Russia 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 145: Rest of Europe 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 148: Rest of Europe 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 151: Rest of Europe 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • ASIA-PACIFIC
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 154: Asia-Pacific 13-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 157: Asia-Pacific 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 160: Asia-Pacific 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 163: Asia-Pacific 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • AUSTRALIA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 165: Australia Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 166: Australia 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 168: Australia Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 169: Australia 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 171: Australia Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 172: Australia 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • INDIA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 174: India Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 175: India 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 176: India Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 177: India Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 178: India 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 179: India Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 180: India Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 181: India 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 183: South Korea Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 184: South Korea 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 186: South Korea Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 187: South Korea 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 189: South Korea Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 190: South Korea 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • LATIN AMERICA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 201: Latin America Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 202: Latin America 13-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 204: Latin America Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 205: Latin America 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 207: Latin America Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 208: Latin America 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 210: Latin America Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 211: Latin America 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 213: Argentina Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 214: Argentina 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 216: Argentina Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 217: Argentina 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 219: Argentina Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 220: Argentina 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 222: Brazil Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 223: Brazil 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 225: Brazil Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 226: Brazil 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 228: Brazil Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 229: Brazil 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 231: Mexico Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 232: Mexico 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 234: Mexico Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 235: Mexico 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 237: Mexico Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 238: Mexico 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 241: Rest of Latin America 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 244: Rest of Latin America 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 247: Rest of Latin America 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • MIDDLE EAST
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2025 through 2032 and % CAGR
    • TABLE 249: Middle East Historic Review for Bovine Respiratory Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 250: Middle East 13-Year Perspective for Bovine Respiratory Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 252: Middle East Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 253: Middle East 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 255: Middle East Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 256: Middle East 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 258: Middle East Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 259: Middle East 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 261: Iran Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 262: Iran 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 264: Iran Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 265: Iran 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 267: Iran Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 268: Iran 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 270: Israel Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 271: Israel 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 273: Israel Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 274: Israel 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 276: Israel Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 277: Israel 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 280: Saudi Arabia 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 283: Saudi Arabia 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 286: Saudi Arabia 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 288: UAE Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 289: UAE 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 291: UAE Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 292: UAE 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 294: UAE Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 295: UAE 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 298: Rest of Middle East 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 301: Rest of Middle East 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 304: Rest of Middle East 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032
  • AFRICA
    • Bovine Respiratory Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 306: Africa Historic Review for Bovine Respiratory Disease Treatment by Drug Type - Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 307: Africa 13-Year Perspective for Bovine Respiratory Disease Treatment by Drug Type - Percentage Breakdown of Value Sales for Antibiotics Drug Type, Anti-Inflammatories Drug Type, Vaccines Drug Type and Antiparasitics Drug Type for the Years 2020, 2026 & 2032
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 309: Africa Historic Review for Bovine Respiratory Disease Treatment by Administration Route - Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 310: Africa 13-Year Perspective for Bovine Respiratory Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration Route, Intramuscular Administration Route, Subcutaneous Administration Route and Oral Administration Route for the Years 2020, 2026 & 2032
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2025 through 2032 and % CAGR
    • TABLE 312: Africa Historic Review for Bovine Respiratory Disease Treatment by Application - Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2024 and % CAGR
    • TABLE 313: Africa 13-Year Perspective for Bovine Respiratory Disease Treatment by Application - Percentage Breakdown of Value Sales for Therapeutic Application, Prophylactic Application, Diagnostic Application and Supportive Care Application for the Years 2020, 2026 & 2032

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기